Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology invented at the University of Queensland.

Vicebio is also working on another experimental vaccine targeting RSV, human metapneumovirus and a type of parainfluenza virus that is at an earlier stage of development, Sanofi said.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA.

Researchers have built a high-resolution, 3D structure of Powassan virus (POWV). Understanding the structure of the virus is necessary for understanding viral transmission.

Understanding the structure of the virus is necessary for understanding viral transmission, something Joyce said is not well understood.

But now, it has learnt to co-exist with other respiratory viruses, like influenza viruses, adenovirus, rhinovirus, RSV, and parainfluenza viruses, which flourish during monsoon.

Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children.

Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform to be broadly effective against viruses of the paramyxoviridae family have ...

The film discusses the nature of viruses, including their structure, reproduction, and the diseases they cause. It explains how viruses are incredibly small and require a host cell to survive and ...

The "Parainfluenza Virus Infection Epidemiology Forecast 2034" report has been added to ResearchAndMarkets.com's offering. The "Parainfluenza virus infection (PIV) Epidemiology Forecast 2034 ...

TheParainfluenza Virus Infection Epidemiology Forecast Research Report 2024-2034: Focus on United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan - ResearchAndMarkets.com ...